HomeCompareBPTS vs VICI

BPTS vs VICI: Dividend Comparison 2026

BPTS yields 24.33% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $871.3K in total portfolio value· pulled ahead in Year 6
10 years
BPTS
BPTS
● Live price
24.33%
Share price
$8.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$94.9K
Annual income
$10,445.94
Full BPTS calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — BPTS vs VICI

📍 VICI pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPTSVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPTS + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPTS pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPTS
Annual income on $10K today (after 15% tax)
$2,068.13/yr
After 10yr DRIP, annual income (after tax)
$8,879.05/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $507,390.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPTS + VICI for your $10,000?

BPTS: 50%VICI: 50%
100% VICI50/50100% BPTS
Portfolio after 10yr
$530.6K
Annual income
$308,911.03/yr
Blended yield
58.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

BPTS
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$15.00
+82.5% upside vs current
Range: $15.00 — $15.00
Altman Z
-13.4
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPTS buys
0
VICI buys
0
No recent congressional trades found for BPTS or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPTSVICI
Forward yield24.33%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$94.9K$966.2K
Annual income after 10y$10,445.94$607,376.13
Total dividends collected$59.3K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$15.00$31.60

Year-by-year: BPTS vs VICI ($10,000, DRIP)

YearBPTS PortfolioBPTS Income/yrVICI PortfolioVICI Income/yrGap
1$13,133$2,433.09$11,361$941.49+$1.8KBPTS
2$17,039$2,986.35$13,320$1,481.32+$3.7KBPTS
3$21,852$3,621.00$16,284$2,405.01+$5.6KBPTS
4$27,722$4,340.18$21,040$4,071.78+$6.7KBPTS
5$34,809$5,145.80$29,209$7,285.49+$5.6KBPTS
6← crossover$43,284$6,038.47$44,443$14,006.51$1.2KVICI
7$53,331$7,017.47$75,822$29,512.55$22.5KVICI
8$65,145$8,080.76$148,733$69,726.75$83.6KVICI
9$78,930$9,225.06$344,394$189,413.75$265.5KVICI
10$94,901$10,445.94$966,234$607,376.13$871.3KVICI

BPTS vs VICI: Complete Analysis 2026

BPTSStock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Full BPTS Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this BPTS vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPTS vs SCHDBPTS vs JEPIBPTS vs OBPTS vs KOBPTS vs MAINBPTS vs NNNBPTS vs EPRTBPTS vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.